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More reliable biomarkers using near-patient technologies are needed to improve early diagnosis and 
intervention for patients with renal disease. Infrared (IR) vibrational spectroscopy/microspectroscopy 
is an established analytical method that was first used in biomedical research over 20 years ago. With 
the advances in instrumentation, computational and mathematical techniques, this technology has 
now been applied to a variety of diseases; however, applications in nephrology are just beginning 
to emerge. In the present study, we used attenuated total reflectance Fourier transform infrared 
(ATR-FTIR) spectroscopy to analyze urine samples collected from rodent models of inflammatory 
glomerulonephritis (GN) as well as from patients with crescentic GN, with the aim of identifying 
potential renal biomarkers; several characteristic mid-IR spectral markers were identified in urine 
samples. Specifically, a 1545 cm−1 band increased in intensity with the progression and severity of GN 
in rats, mice and humans. Furthermore, its intensity declined significantly in response to corticosteroid 
treatment in nephritic rats. In conclusion, our results suggest that specific urinary FTIR biomarkers may 
provide a rapid, sensitive and novel non-invasive means of diagnosing inflammatory forms of GN, and 
for real-time monitoring of progress, and response to treatment.
Despite ongoing efforts to develop effective treatments for kidney diseases, the number of patients with chronic 
kidney disease (CKD) and end-stage renal failure (ESRF) continues to grow worldwide1. The conventional renal 
biomarkers of serum creatinine (Scr) and proteinuria (or albuminuria) are used widely, but are relatively insen-
sitive in that they change later in disease. Scr is also affected by several non-renal factors such as age, gender and 
body mass2. For many patients, by the time a rise in Scr is detected, 50% of renal function has been lost and the 
presence and extent of proteinuria is highly variable3; moreover, although proteinuria can correlate with disease 
severity, it cannot distinguish between acute and chronic forms of injury4, 5. The result is that renal disease is often 
detected too late for any beneficial therapeutic intervention, which can lead to poor renal outcomes. Renal biopsy 
is currently a reliable method of diagnosing the nature and extent of renal disease, but repeated biopsy is limited 
in a clinical setting, because of its invasiveness. Thus, sensitive non-invasive biomarkers of early renal injury are 
needed for prompt detection and monitoring of patients, and for better clinical trial design.
Fourier transform infrared (FTIR) spectroscopy measures absorption of IR light caused by transitions between 
energy levels of molecular vibrational normal modes6, 7. FTIR spectroscopy covers the 6000–200 cm−1 region of 
the electromagnetic spectrum. Particularly useful when analyzing biological samples is the mid-IR fingerprint 
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region of 1800-900 cm−1 where many molecules exhibit characteristic absorption bands. For example, protein 
peptide bonds have amide I (1690-1600 cm−1) and amide II (1575-1480 cm−1) bands; deoxyribonucleic acid has 
symmetric and asymmetric PO2− stretches at 1244 cm−1 and 1089 cm−1, respectively7–9. FTIR spectroscopy and 
FTIR microscopy imaging have been increasingly applied to diseases such as cancer by analyzing biofluids, tissue 
sections or cells10–19. The spectral data can provide rapid quantitative and qualitative measurements of biochem-
ical changes caused by pathologies and without chemical modification of the original fluid or tissue samples. 
FTIR spectroscopy/microspectroscopy has been investigated recently as a potential diagnostic tool in various 
forms of kidney diseases20–23. Its main advantages are that it is ‘manipulation-free’, chemically non-destructive, 
cost-effective, and potentially operator-independent, unlike many other spectroscopy-based analytical platforms 
applied to urine, such as mass spectroscopy and nuclear magnetic resonance. However, despite a continuous 
increase in applications of biomedical spectroscopy, several challenges encountered during clinical-translational 
research should be considered to overcome them. For instance, large-scale randomised control trials and incorpo-
ration with current standard diagnositc methods are required to prevent the bias from small sample studies, and 
further validate spectral biomakers or signatures for diagnositc or prognostic purposes7, 24. Besides, appropriate 
standarization (e.g. sample spectral collection and preanalytic processing), the roubustness of analytic methods, 
and automation will be helpful to facilitate real clinical translation with the respect to technical issue7, 25, 26.
In the present study, our aim was to identify specific FTIR spectral markers of renal injury in rodent models of 
acute and progressive glomerulonephritis (GN), and human inflammatory (crescentic) GN. Promising markers 
were assessed as a means of monitoring therapeutic responses and their relationship to extents of proteinuria as 
measured by standard clinical methods.
Methods
Animal models of glomerulonephritis (GN). All animal methods were carried out in accordance with 
the relevant guidelines of Animals (Scientific Procedures) Act 1986 authorized by the Home Office, United 
Kingdom (UK). The animal experimental protocols were approved by Imperial College London, UK.
The rat model of progressive crescentic GN. Wistar Kyoto (WKY) rats (Charles River Laboratories, 
London) weighing around 200–300 gm were used. Nephrotoxic nephritis (NTN) was induced in male WKY 
rats by a single intravenous injection of 0.1 ml rabbit anti-rat glomerular basement membrane antiserum. NTN 
in WKY rats is a reproducible rodent model of progressive glomerulonephritis, presenting histological features 
similar to human crescentic GN27. Following the injection of nephrotoxic serum (NTS), the rats were divided 
into four groups for study at different time points after injection that have distinct pathophysiological character-
istics: (1) NTN at 8 days (d8 NTN, n = 20): acute inflammation, (2) NTN at 14 days (d14 NTN, n = 18): severe 
inflammation, (3) NTN at 21 days (d21 NTN, n = 17): early renal fibrosis, and (4) NTN at 28 days (d28 NTN, 
n = 18): late fibrosis and renal failure. Findings were compared with that from age-matched healthy normal WKY 
rats (n = 34). The rats were housed in metabolic cages with free access to food and water for 24 hours to collect 
urine. All of the urine samples were centrifuged at 1800 rpm (4 °C) for 5 minutes and then frozen at −20 °C for 
later measurements.
A mouse model of spontaneous lupus nephritis. Female F1 hybrids of New Zealand Black and New 
Zealand White, (NZB x NZW) F1, mice were purchased from Harlan Laboratories UK. This mouse strain is capa-
ble of developing spontaneous autoimmune glomerulonephritis that resembles human lupus nephritis (LN)28. 
Twenty-four hour urine was collected from 14 (NZB x NZW) F1 mice aged between five and eight months. Urine 
dipstick testing in 11 mice ranged from negative to 1 + protein (i.e. 5 mice were negative, 5 mice had trace, and 
one mouse had 1 + protein, respectively); 2 mice had 2 + protein and 5 mice had 3 + to 4 + protein.
Figure 1. Fourier transform infrared (FTIR) analysis of rat urine: urine spectral normalization, second 
derivative conversion and integration. (a) Absorbance spectra of each dried urine sample were recorded from 34 
normal rats (upper graph). Later, the urine spectra were individually normalized to the urea band at 1450 cm−1 
(1477~1427 cm−1) followed by transformation to 2nd derivative forms (lower graph). (b) The urine 1545 cm−1 
peak was integrated by measuring the peak area between 1558 and 1532 cm−1.
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Corticosteroid treatment in a rat model of experimental crescentic GN. Rats were grouped into: 
(1) normal WKY rats (n = 4) as controls; (2) NTN-treated WKY rats (n = 6) given dexamethasone treatment 
(0.25 mg/kg) by intraperitoneal (ip) injection (Sigma-Aldrich, UK) every 4 days; (3) NTN-treated WKY rats 
(n = 6) given vehicle only (0.25 mg/kg ip of sterile 1xPBS) every 4 days. Twenty-four hour urine was collected 
from nephritic rats following the injection of NTS at 4 days, 8 days, 14 days, 21 days and 28 days, and compared 
with normal and untreated rats at each time point.
Clinical crescentic GN and other kidney diseases. Twenty-four antineutrophil cytoplasmic antibody 
(ANCA) vasculitis patients (26–82 years old) and 11 healthy volunteers (23–56 years old) were studied follow-
ing written informed consent; this study protocol had been approved by the local research ethics committee 
(NRES Committee London-West London [REC reference 04/Q0406/25]) and the study was approved by Imperial 
College Healthcare NHS Trust. All methods were performed in accordance with the guidelines and regulations 
issued by the Joint Health Compliance Office, Academic Health Science Centre, Imperial College London and 
Imperial College Healthcare NHS Trust, United Kingdom. Urine samples were collected in outpatient clinics 
at the Hammersmith Hospital, Imperial College London, and centrifuged at 1800 rpm (4 °C) for 10 minutes. 
FTIR analysis was then done soon after collection. Healthy volunteers were not known to have kidney disease 
or hypertension or diabetes, and their dipstick urine tests were negative for protein, blood and sugar. The 24 
vasculitis patients were biopsy proven crescentic GN showing various degrees of kidney damage and were being 
treated with corticosteroid, cyclophosphamide, azathioprine or mycophenolate mofetil, according to a standard 
protocol. The following information was retrieved from medical records: patient age, gender, urinalysis, urinary 
protein-to-creatinine ratio (uPCR), estimated glomerular filtration rate (eGFR), the titer of ANCA and results 
of histological study. Crescentic GN patients with eGFR ≧ 60 ml/min/1.73 m2 were considered to have mild renal 
impairment, whereas crescentic GN patients with eGFR <60 ml/min/1.73 m2 were considered to have moderate 
to severe renal impairment. Furthermore, the remission of ANCA-associated crescentic GN was defined by the 
absence of ANCA and urine dipstick-negative for protein or uPCR ≦ 45 mg/mmol. In contrast, active crescentic 
GN patients had positive ANCA and an uPCR > 45 mg/mmol.
Proteinuria measurement. The sulphosalicylic acid (SSA) assay was used to quantify protein excretion in 
rat urine; for mouse urine, the level of proteinuria was determined using dipstick testing only.
Urine Protein Ultrafiltration. Urine samples of normal, day 8 NTN and day 21 NTN rats were filtered 
through different sizes of AMICON Ultra 4 ml Centrifugal Filters (Merck Millipore, UK) with molecular weight 
cut-offs (MWCO) of 10,000 (10 K), 30,000 (30 K), 50,000 (50 K) and 100,000 (100 K), respectively. Subsequently, 
the ultrafiltrates were collected and then analyzed using ATR-FTIR.
Figure 2. Protocol for urine handling and analysis. Urine is firstly centrifuged and the supernatant is diluted 
with distilled water and a 5 μl sample is dried on to the ATR prism surface. After drying, a sample spectrum is 
recorded. The raw sample spectra are pre-processed by water vapor subtraction, normalization to the peak of 
urea and second derivative conversion. Features of interest are then quantitated by integration and statistical 
assessment (Origin Pro 9.1).
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ATR-FTIR measurement. After thawing at room temperature, urine samples from rats, mice and humans 
were prepared by diluting with distilled water to 1:30, 1:20 or 1:40 (urine: water). Pipetting 5 µl of diluted urine 
was pipetted onto a silicon ATR prism (SensIR, 3 mm diameter, 3 reflections) and dried by nitrogen gas at a 
flow rate of 400 mL/min. Spectra were subsequently recorded with a Bruker Optics, Germany, IFS 66/S FTIR 
spectrometer equipped with an Mercury cadmium telluride (MCT)-A detector cooled using liquid nitrogen. 
All absorbance spectra were recorded in the 4000–800 cm−1 frequency range versus a clean prism background. 
Each spectrum was computed from the average of 500 interferograms at 4 cm−1 resolution using the clean prism 
surface for recording of the background spectrum. The prism surface was cleaned using distilled water and eth-
anol between samples. The resultant FTIR absorbance spectra were analyzed with Bruker 6.5 and Origin Pro 9.1 
software.
Urine spectral assignment: processing and analysis. Absorbance spectra were pre-processed by 
removal of any contribution from water vapor, followed by normalization to the peak of urea at 1450 cm−1 and 
Figure 3. Five features of interest identified in experimental glomerulonephritis. (a) The average normalized 
second derivative FTIR spectra of urine obtained from normal WKY rats and different stages of NTN rats. (b) 
Peaks of interest (1668 cm−1, 1545 cm−1, 1242 cm−1, 1107 cm−1, and 1033 cm−1) potentially relevant to renal 
inflammation and/or fibrosis. (c) The PCA bioplot displays the correlations between the five spectral markers 
and individual urine sample of normal rats (n = 34) and d28 NTN rats (n = 18, there was one outlier excluded 
from this group). PC1 and PC2 explained 75.7% of total variance.
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conversion to the second derivative forms Fig. 1(a). The rationale for choosing urea rather than creatinine for 
spectral normalization is that urea is a dominant component of urine FTIR spectra and is a reasonable measure 
of urine concentration, whereas in small animals such as rats and mice, the spectrum for urinary creatinine is too 
weak to provide a reliable measure of urinary dilution. Next, features of interest were quantified by integration 
between two frequency limits and intensities were compared between different disease states or treatment groups 
Fig. 1(b). The scheme of FTIR spectral acquisition and analysis of urine is illustrated in Fig. 2. Comparisons of the 
Figure 4. The 1668 cm−1, 1545 cm−1 and 1033 cm−1 IR peaks behavior in relation to renal inflammation, the 
progression of renal injury and renal fibrosis. The intensity of the urinary 1668 cm−1 spectral marker (a) was 
significant decreased in both d8NTN and d14 NTN groups (inflammation) compared with the normal group 
and the fibrotic group (i.e. d21NTN and d28NTN). The intensity of the urinary 1545 cm−1 spectral marker (b) 
increased as nephritis progressed. The 1033 cm−1 spectral marker (c) showed a marked reduction in the fibrotic 
group compared to the normal and inflammatory groups. (Boxes are mean ± SD. Data was analyzed by one-way 
ANOVA and subsequent Fisher’s LSD post hoc test for mean comparisons).
Figure 5. (a) The PCA biplot represents the locations of 2nd derivative spectra of 107 urine samples and the 
correlations among the three potential urinary spectral markers (1668 cm−1, 1545 cm−1 and 1033 cm−1 bands) 
on the first two principal components (85.1% of total variance). (b) 3D scatter plot displayig the separation of 
normal, inflammatory and fibrotic NTN groups.
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average normalized second derivative spectra of each nephritic group with that of the healthy control revealed six 
features of interest as possible markers to distinguish normal from nephritic groups Fig. 3(a) and (b). Integrated 
areas of these features were obtained from individual samples [i.e. normal rats (n = 34), day 8 NTN rats (n = 20), 
day 14 NTN rats (n = 18), day 21 NTN rats (n = 17) and day 28 NTN rats (n = 18)]. The results were then ana-
lyzed by a pairwise principal component analysis (PCA) for exploration of the most significant spectral responses 
Parameters
Frequency 
limits for 
integration
Normal rats 
(n = 34)
D8 NTN rats 
(n = 20)
D14 NTN 
rats (n = 18)
D21 NTN 
rats (n = 17)
D28 NTN 
rats (n = 18)
Urinary 1668 cm−1 peak 1676–1664 cm−1
Peak intensity
30.5 ± 1.6
10.5 ± 1.8* 12.6 ± 2.1* 27.1 ± 3.8 32.0 ± 4.0
p-value 
(nephritis vs. 
normal)
<0.001 <0.001 0.342 0.670
Urinary 1545 cm−1 peak 1558–1532 cm−1
Peak intensity
17.0 ± 1.6
249.2 ± 13.5* 314.0 ± 13.4* 369.8 ± 17.3* 350.3 ± 24.2*
p-value 
(nephritis vs. 
normal)
<0.001 <0.001 <0.001 <0.001
Urinary 1242 cm−1 peak 1254–1230 cm−1
Peak intensity
15.8 ± 0.7
30.9 ± 1.7* 31.8 ± 1.6* 37.0 ± 1.6* 33.9 ± 1.5*
p-value 
(nephritis vs. 
normal)
<0.001 <0.001 <0.001 <0.001
Urinary 1107 cm−1 peak 1122–1092 cm−1
Peak intensity
26.3 ± 2.9
21.1 ± 3.4 21.3 ± 2.9 21.0 ± 2.7 30.7 ± 5.0
p-value 
(nephritis vs. 
normal)
0.245 0.282 0.263 0.349
Urinary 1033 cm−1 peak 1047–1022 cm−1
Peak intensity
40.9 ± 1.9
33.4 ± 3.9* 36.1 ± 3.6 11.9 ± 1.6* 17.7 ± 3.1*
p-value 
(nephritis vs. 
normal)
0.044 0.215 <0.001 <0.001
Proteinuria (mg/dl)
p-value 
(nephritis vs. 
normal)
3.7 ± 0.3
77.4 ± 6.9* 106.6 ± 4.2* 151.3 ± 9.1* 109 ± 9.8*
<0.001 <0.001 <0.001 <0.001
Urine creatinine(mmol/L)
p-value 
(nephritis vs. 
normal)
4.7 ± 1.7
3.7 ± 1.1* 3.3 ± 1.3* 3.2 ± 0.7* 2.6 ± 0.3*
0.008 <0.001 <0.001 <0.001
Urine urea (mmol/L)
p-value 
(nephritis vs. 
normal)
457.5 ± 146.8
304 ± 79.7* 256.1 ± 78.4* 236.9 ± 37.3* 234.1 ± 43.1*
<0.001 <0.001 <0.001 <0.001
Table 1. Summary of potential IR marker bands, proteinuria, creatinine and urea concentrations in urine 
samples of normal and NTN rats. The data were expressed as mean ± SD and analyzed by one-way ANOVA 
followed by Fisher’s LSD post hoc test. Statistical significance (*) was set as p-valve < 0.05.
Figure 6. (a) Longitudinal study of the intensity of the urinary 1545 cm−1 band in NTN rats treated with DXM 
(started after urine collections on day 4) (red) compared with the normal (orange) and vehicle-treated NTN rats 
(blue). It was apparent that the peak intensities were reduced in response to DXM treatment. (b) Longitudinal 
analysis of the intensity of the urinary 1033 cm−1 band marker in the treatment group (red) compared with 
healthy controls (orange) and the vehicle group (blue). From day 14 to day 28, the vehicle treated group had 
a major reduction in the peak intensity whereas these changes in the spectral peaks were less in the treatment 
group (p < 0.05).
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in the multivariate IR data set, and discrimination of spectroscopic changes between different experimental 
groups. In addition, the one-way Analysis of Variance (ANOVA) followed by Fisher’s Least Difference Significant 
(LDS) post hoc test was conducted to verify the significance of the selected spectral markers (Table 1). The data are 
expressed as means with standard deviations (SD). The level of statistical significance considered p < 0.05. Origin 
Pro 9.1 was used for all the statistical analyses.
Results
Three potential spectral markers (i.e. the bands at the positions of 1668 cm−1, 1545 cm−1 and 
1033 cm−1) were identified in dried urine that related to inflammation, progression of GN and 
chronic renal fibrosis, respectively. Initially five potential peaks of interest were identified by compari-
sons of the average normalized second derivative spectra of each nephritic group with that of the healthy control 
Fig. 3(a) and (b). Subsequently, PCA analysis was used for differentiation of these spectral data into two catego-
ries, normal rats versus rats at day 28 NTN. The PCA loadings and scatter plots displayed the five spectral features 
and individual samples on the first two components Fig. 3(c). The first principal component (PC1) (46.6%), the 
second principal component (PC2) (29.1%) and the third principal component (PC3) (14.9%) accounted for 
90.6% of total variance for the six spectroscopic changes. The loading plot also illuminated that the spectral fea-
tures at 1545 cm−1 and 1242 cm−1 were associated with PC1 while the spectral features a 1107 cm−1 and 1033 cm−1 
were associated with PC2. The 1668 cm−1 spectral marker was more related to PC3. In Table 1, it showed the 
results of quantitation of these five features and the concentrations of urine urea and creatinine. The statistical sig-
nificances of all five possible urinary spectral markers were further tested by one-way ANOVA and Fisher’s LDS 
post hoc test (Fig. 4), and three of the five IR features were found to be were statistically significant as potential 
biomarkers of kidney injury in experimental GN. In Fig. 5(a), the PCA biplot simultaneously displays informa-
tion on locations of individual samples and correlations among these three potential IR features: the 1668 cm−1, 
1545 cm−1 and 1033 cm−1 bands. PC1 (51.5% of total variance) appeared to correlate strongly with the 1545 cm−1 
Figure 7. (a) The urinary 1545 cm−1 mid-infrared marker had a positive correlation with proteinuria during 
the time course of NTN. (b) Although the level of proteinuria increased gradually along with progression of 
nephritis, there was a manifest sudden drop at d28 NTN (p < 0.05) probably caused by a fall in glomerular 
filtration rate due to severe renal injury.
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and 1033 cm−1 spectral markers, which had loadings with largest negative and positive magnitudes, respectively. 
PC2 (33.6% of total variance) had a higher correlation with the 1668 cm−1 spectral marker. This spectral pattern 
correlation was illustrated in a three-dimensional (3D) scatter plot in Fig. 5(b).
Taken together, the first candidate marker was the band at 1668 cm−1. Its band intensities in both day 8 and 
d14 NTN groups (inflammatory groups) were clearly distinguishable from those in the normal and fibrosis 
groups (i.e. day 21 and day 28 NTN rats) Fig. 4(a). The second candidate was the 1545 cm−1 band Fig. 4(b). Its 
peak intensity in each nephritic group (i.e. day 8, day 14, day 21 and day 28 NTN rats) was significantly higher 
than in normal healthy rats (p < 0.05). Moreover, its intensity continued to increase in accordance with the pro-
gression of GN injury, except for a slight reduction in the day 28 NTN group. The third peak of interest was the 
band at 1033 cm−1 Fig. 4(c). Its differences in intensity between normal, day 8 NTN and day 14 NTN groups were 
not significant. Nevertheless, there was a significant decrease in the peak intensity observed in both the day 21 
NTN and day 28 NTN groups compared with either the normal group or the inflammatory groups (i.e. day 8 
NTN and day 14 NTN rats) (p < 0.05).
These findings indicate that these spectral features 1668 cm−1, 1545 cm−1 and 1033 cm−1 may be useful urinary 
biomarkers of acute inflammatory renal injury and renal fibrosis.
Figure 8. (a) Normalized 2nd derivative IR spectra of seven (NZB x NZW) F1 mice with negative to 1 + protein 
by dipsticks (i.e. negative to trace protein for the samples including N1, N2, N4, N5, N6 and N7, and 
1 + proteinuria for the sample N3 (b) Normalized 2nd derivative IR spectra of seven (NZB x NZW) F1 mice 
with 2 + proteinuria (the samples of LN1 and LN4) and 3 + proteinuria (the samples of LN2, LN3, LN5, LN6 
and LN7). (c) The intensity of the urinary 1545 cm−1 spectral marker in LN mice with negative/1 + protein 
(n = 7), LN mice with 2 + protein (n = 2) and LN mice with 3 + protein (n = 5). The mice with significant 
proteinuria (3 + positive) had the highest level of the 1545 cm−1 peak intensity compared to the other two 
groups, but there was no significant difference between mice with negative and mild proteinuria (≤2 + protein). 
(The data are expressed as mean ± SD, analyzed by one way ANOVA with Fisher’s LSD post hoc test)
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The intensities of the 1545 cm−1 and 1033 cm−1 spectral markers were altered in response to 
corticosteroid treatment in NTN rats. In the corticosteroid treatment experiments, the healthy con-
trol group had a constant intensity level of of the urinary 1545 cm−1 spectral marker, whereas in the vehicle 
treated nephritic (NTN) group, its intensity increased over time as GN injury progressed Fig. 4(b). Moreover, the 
intensity of the urinary 1545 cm−1 spectral marker declined significantly in response to dexamethasone (DXM) 
treatment in the NTN rats Fig. 6(a). The intensity of the urinary 1033 cm−1 spectral marker remained constant 
in the healthy control group, whereas in the vehicle treated NTN group its intensity declined over time Fig. 4(c). 
However, the peak intensity in the DXM treated group increased following administration of DXM Fig. 6(b). 
There was no consistent change in the urinary 1668 cm−1 spectral marker in the DXM treated NTN group. These 
findings suggest that FTIR can be used to monitor a therapeutic response in inflammatory GN by detecting 
changes in the 1545 cm−1 and/or 1033 cm−1 spectral biomarkers in urine.
The urinary 1545 cm−1 spectral marker had a positive correlation with proteinuria during the 
time course of NTN and was more reliable in assessing the severity of renal injury. Figure 7(a) 
compares the longitudinal patterns of the urinary 1545 cm−1 spectral marker with the development of proteinuria 
in the NTN model. During earlier stages of renal injury its peak intensity correlated with the degree of proteinuria 
as NTN injury progressed. Figure 7(b) shows that the level of proteinuria increased gradually as NTN evolved, 
but that there was a significant drop at day 28 of NTN (p < 0.05) when renal failure has become established in 
this model.
The urinary 1545 cm−1 spectral marker was also useful in detecting severe murine lupus nephri-
tis. (NZB x NZW) F1 mice develop spontaneous autoimmune GN with varying severity. Therefore, we inves-
tigated whether the urinary FTIR urine spectral biomarkers could be used to assess the severity of murine lupus 
nephritis. The FTIR spectra of urine obtained from 14 (NZB x NZW) F1 mice were analyzed following the 
method described above and for the same potential spectral marker bands. Figure 8(a) and (b) illustrate the 
Figure 9. Comparison of FTIR urine spectra of patients with crescentic glomerulonephritis (CrGN) with those 
from healthy volunteers. The normalized 2nd derivative spectra of urine of (a) healthy volunteers (n = 11) and 
(b) CrGN patients (n = 24) are shown. The 1545 cm−1 band was significantly higher in CrGN patients [p < 0.05, 
graph (c)]. (d) The intensity of the 1545 cm−1 band is significant higher in patients with severe/moderate CrGN 
patients (eGFR < 60 ml/min/1.73 m2) than in both healthy volunteers and mild CrGN patients (eGFR ≥ 60 ml/
min/1.73 m2). (The data are expressed as mean ± SD as determined by sample t test or one-way ANOVA with 
Fisher’s LSD post hoc test).
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normalized 2nd derivative spectra of 7 mice with negative to 1 + proteinuria on dipstick and with 2 + to 3+/4+ 
proteinuria on dipstick, respectively. The 1545 cm−1 spectral marker was found to correlate with the extent of 
lupus nephritis according to the degree of proteinuria, as shown in Fig. 8(c). (NZB x NZW) F1 lupus mice with 
3 + /4 + proteinuria had a statistically higher peak intensity than either the mice without proteinuria or with only 
mild proteinuria (the range from 1 + to 2 + positive in urine dipstick); the peak intensity difference between lupus 
mice with negative proteinuria and with mild proteinuria was not significant. These findings indicate the potential 
for the urinary 1545 cm−1 spectral marker to be a diagnostic biomarker of severe lupus nephritis.
The intensity of the urinary 1545 cm−1 spectral marker was also significantly higher in patients 
with moderate/severe crescentic GN. The intensity of the urinary 1545 cm−1 spectral marker was con-
sistently different between healthy volunteers and 24 patients with crescentic GN who were diagnosed with 
ANCA associated vasculitis Fig. 9(a) and (b). Overall, its intensity was elevated in the GN patients compared 
with healthy volunteers (p < 0.05) Fig. 9(c). As shown in Fig. 9(d), it was also evident that moderate-to-severe GN 
patients with an eGFR were <60 ml/min/1.73 m2 and active disease or in remission had a higher 1545 cm−1 band 
intensity than GN patients with eGFR ≥ 60 ml/min/1.73 m2.
The 1545 cm−1 band of the urine ultrafiltrates collected from AMICON Ultra centrifugal fil-
ters of MWCO 100 K increased its intensity with the severity of NTN. Figure 10 shows that the 
1545 cm−1 band in the urine ultrafiltrates collected from 100 K AMICON centrifugal filters increases intensity 
from normal, day 8 NTN to day 21 in NTN rats, consistent with the results during NTN progression of Fig. 4(b). 
The nephritic urine ultrafiltrates obtained from 10 k, 30 k and 50 K AMICON centrifugation devices did not show 
an increase of the 1545 cm−1 band.
Discussion
By applying ATR-FTIR spectroscopy to urine samples from rodent models of acute inflammatory GN, we have 
identified several characteristic urinary spectral markers of acute and chronic renal injury. Of these, the urinary 
1545 cm−1 band was also diagnostically applicable to murine lupus nephritis and human GN. The same biomark-
ers were also useful for monitoring the therapeutic response to steroid therapy.
Several studies have reported the application of FTIR to routine clinical chemistry analyses and disease diag-
nostics in fluids, cells and tissues24, 29–33. Along with existing applications in various types of cancer, bone and 
neurodegenerative diseases34–36, there are ongoing initiatives to encourage work on infrared based technologies 
Figure 10. The 1545 cm−1 peak intensity of the urine ultrafiltrates. Urine samples of normal, d8 NTN and d21 
NTN rats were filtered through AMICON centrifugal filters with different M cutoffs of 10 K, 30 K, 50 K and 
100 K, and the ultrafiltrates were analyzed. The 1545 cm−1 component was only observed in the ultrafiltrate 
collected from MWCO 100 AMICON filter as it increased gradually from normal, d8 NTN (inflammation) to 
d21 NTN (fibrosis).
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and their wider application to clinical medicine37 (https://clirspec.org/uk-network/). However, so far there are few 
applications to kidney diseases. Two recent reports have described renal tissue FTIR using renal biopsy material 
to detect and quantify fibrosis and inflammation, and to diagnose diabetic nephropathy, but in neither report 
were there corresponding or matching analyses of urine20, 21. Application of FTIR spectroscopy to tissue analyses 
is a potentially useful adjunct to current histological techniques for refining pathological classification of renal 
disease, but it still depends on obtaining renal tissue samples invasively. By contrast, our study has focused on 
detecting potentially easy to acquire urinary biomarkers of renal injury in a reproducible rodent model of inflam-
matory and progressive GN, as well as their validation in a cohort of patients with crescentic GN.
The band at 1545 cm−1 is likely to be attributable to the amide II band of the peptide bonds of urinary protein. 
Hence, it is a measure for urinary protein and has the potential to be an earlier and more sensitive marker of pro-
gression of renal injury than currently measured proteinuria. In the model of NTN in WKY rats, albuminuria can 
be detected by rocket immunoelectrophresis on day 4 following injection of nephrotoxic serum27. The Amicon 
ultracentrifugal experiments reported here indicate that the protein responsible was only observed in the urine 
ultrafiltrate collected from 100 K AMICON Ultra filter (Fig. 10). This implies that its relative molecular mass is 
>50 kDa, which could be albumin (Mr = 68 kDa)38 or other high Mr protein. In relation to the bands at 1668 cm−1 
and 1033 cm−1, the majority of the absorption around 1668 cm−1 band probably comes from urea and creatinine. 
There will also be amide I band of protein present, but this will be no greater than the amide II in intensity. If 
the change in 1668 cm−1 band is due to protein, then its changes should match changes in the 1545 cm−1 amide 
II band. The 1033 cm−1 band could be carbohydrate, ribose of RNA, phosphate free or in lipid and other possi-
bilities. However, the FTIR spectra of biological systems are very complex due to the overlapping absorption of 
multiple components. Based on contemporarily available data in IR libraries, the information seems insufficient 
to elucidate the molecular models corresponding to these potential urinary spectral markers and further work is 
needed.
The standardized method of analyzing FTIR spectra of dried urine samples described here is applicable and 
optimal for both animal (e.g. rats and mice) and human samples. Three characteristic urinary spectral makers 
(1668 cm−1, 1545 cm−1 and 1033 cm−1) were identified in experimental GN, which seem to be linked to the acute 
inflammatory, progressive and fibrotic phases of this GN model, respectively. As to potential for translation to the 
clinic, the 1545 cm−1 peak is the most clear and universal marker of progressive kidney diseases. This is because 
this spectral marker was evident in the rat and mouse models of crescentic GN and lupus nephritis, as well as 
in patients with ANCA-associated vasculitis and GN. A larger number of patients with more diverse causes of 
kidney disease will be need to be explored to establish the value of the spectral markers we have identified in the 
present study, and to test the wider application of FTIR technique in clinical nephrology. However, the relative 
simplicity and convenience in handling urine samples, and the potential for a higher throughput, compared with 
other spectroscopic methods currently being applied to urine, makes this a worthwhile endeavor.
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